Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H13ClN2O |
Molecular Weight | 284.74 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1(N2CCN=C2C3=CC=CC=C13)C4=CC=C(Cl)C=C4
InChI
InChIKey=ZPXSCAKFGYXMGA-UHFFFAOYSA-N
InChI=1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2
Molecular Formula | C16H13ClN2O |
Molecular Weight | 284.74 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Mazindol is an amphetamine-like medicine which was developed by Sandoz in 1967 and approved by FDA for the treatment of obesity and Duchenne muscular dystrophy under the names Sanorex and Mazanor. The exact mechanism of action is unknown, but possibly involves the stimulation of beta-adrenergic receptors and inhibition of monoamine reuptake. Both Sanorex and Mazanor were withdrawn from the market by reason other than safety. NLS Pharma now is developing mazindol for Attention Hyperactivity Disorder in adults (phase II).
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.09 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27066959/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MAZINDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
35.63 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27066959/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MAZINDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27066959/ |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
MAZINDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Pharmaceutical cost savings of treating obesity with weight loss medications. | 1999 Nov |
|
Anticocaine catalytic antibodies have no affinity for RTI compounds: implications for treatment. | 2001 Aug |
|
Dopamine transporter binding in the rat striatum is increased by gestational, perinatal, and adolescent exposure to heptachlor. | 2001 Dec |
|
[Monoaminergic anorectic agents]. | 2001 Nov |
|
1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3. | 2003 Apr |
|
Obesity. | 2003 Dec |
|
Changes in function and ultrastructure of striatal dopaminergic terminals that regenerate following partial lesions of the SNpc. | 2003 Jul |
|
Risk of valvular heart disease associated with use of fenfluramine. | 2003 Jun 11 |
|
Rapid reduction of ATP synthesis and lack of free radical formation by MPP+ in rat brain synaptosomes and mitochondria. | 2003 Jun 13 |
|
Discriminative stimulus effects of (-)-ephedrine in rats: analysis with catecholamine transporter and receptor ligands. | 2003 Jun 5 |
|
GM1 enhances dopaminergic markers in the brain of aged rats. | 2003 Oct |
|
Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA. Site of action, Na+ dependence, and structure-activity relationship. | 2003 Oct 10 |
|
Strain differences in the distribution of dopamine transporter sites in rat brain. | 2003 Sep |
|
Dual effects of intermittent or continuous L-DOPA administration on gene expression in the globus pallidus and subthalamic nucleus of adult rats with a unilateral 6-OHDA lesion. | 2003 Sep 15 |
|
Differential effects of prolonged high frequency stimulation and of excitotoxic lesion of the subthalamic nucleus on dopamine denervation-induced cellular defects in the rat striatum and globus pallidus. | 2004 Dec |
|
Obesity. | 2004 Jun |
|
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. | 2004 Jun |
|
Perinatal heptachlor exposure increases expression of presynaptic dopaminergic markers in mouse striatum. | 2005 Aug |
|
Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. | 2005 Aug |
|
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. | 2005 Jan 25 |
|
Obesity. | 2005 Jun |
|
Neurochemical effects of chronic dietary and repeated high-level acute exposure to chlorpyrifos in rats. | 2005 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: DOI: 10.1604/9780440235378, Catalano J., 'The Women's Pharmacy: An Essential Guide to What Women Should Know About Prescription Drugs' (2008), p.218, Retrieved from https://books.google.es/books?id=WueSNTyQq6sC&dq
The usual dose is 1 mg three times a day an hour before meals or 2 mg once a day an our before lunch.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:11:43 UTC 2023
by
admin
on
Fri Dec 15 15:11:43 UTC 2023
|
Record UNII |
C56709M5NH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
526816
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/15/1444
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
||
|
WHO-VATC |
QA08AA05
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
||
|
FDA ORPHAN DRUG |
876822
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
||
|
NCI_THESAURUS |
C47795
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
||
|
WHO-ATC |
A08AA05
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
||
|
FDA ORPHAN DRUG |
16186
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
||
|
DEA NO. |
1605
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Mazindol
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
6664
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | RxNorm | ||
|
C66057
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
3112
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
2895
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
C56709M5NH
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
244-857-0
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
4020
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
D008454
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
1640
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
DTXSID1023237
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
22232-71-9
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
CHEMBL781
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
SUB08656MIG
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
DB00579
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
100000081747
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
4797
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | |||
|
m7101
Created by
admin on Fri Dec 15 15:11:43 UTC 2023 , Edited by admin on Fri Dec 15 15:11:43 UTC 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |